Workspaces
Log in Sign up

Amgen's Tavneos: FDA Counts Fatal Liver Injuries as Amgen Says It Will Keep the Drug on the Market

Updated

Sources

Amgen's Tavneos: FDA Counts Fatal Liver Injuries as Amgen Says It Will Keep the Drug on the Market

The Tavneos (avacopan) regulatory collapse now has a safety dimension on top of the research-integrity one. FDA's Drug Safety Communication (dated March 31, 2026 on the agency page) reports that after reviewing postmarketing data through Oct 9, 2024, FDA "identified 76 cases of DILI with reasonable evidence of a causal association with avacopan use" — 74 serious, including 54 hospitalizations and 8 deaths — plus "7 reported biopsy-confirmed VBDS" (vanishing bile duct syndrome), 3 of them fatal. Median time-to-onset was 46 days (range 22–140); 66 of 76 cases were reported from Japan. "Although hepatotoxicity is a serious adverse reaction for Tavneos identified in premarket clinical trials and described in product labeling, VBDS and DILI cases with fatal outcomes represent new safety concerns," FDA wrote. The agency now advises liver panel testing every 2 weeks in the first month and monthly for five months, with immediate discontinuation if ALT/AST exceed 3× the upper limit of normal, ALP exceeds 2× ULN, or symptomatic cholestasis (jaundice, pruritus) appears.

The fresh news hook: in a September 19, 2026 Gastroenterology & Endoscopy News report (republished by Pharmacy Practice News), Amgen went on record — "Patient safety always comes first, and we are in regular communication with the FDA about the safety of our medicines" — disclosing that it proposed expanding the Tavneos label to include VBDS back in 2024 and that the request is still pending, and stating: "We remain confident that Tavneos is an important and effective medicine for severe ANCA-associated vasculitis based on robust clinical data and real-world evidence demonstrating the effectiveness and favorable benefit–risk profile." Amgen plans to keep the drug on the market.

That stance lands amid the wider collapse documented in NEJM Retracts Pivotal Trial Behind Amgen's Tavneos Amid Escalating FDA and EMA Regulatory Stand-Off: NEJM's June 29, 2026 retraction of the pivotal ADVOCATE trial paper, the European Commission's August 6 withdrawal of the EU approval, and FDA's own proposal to withdraw the U.S. approval1. Amgen's statement is its clearest public signal yet that it intends to contest withdrawal and retain the U.S. indication rather than pull the drug voluntarily — setting up a formal FDA withdrawal process with no announced endpoint.

  1. An instance of Drug approvals are no longer permanent guarantees of market tenure. — An approved, marketed drug now faces formal withdrawal processes on both sides of the Atlantic while its maker contests retention — approval tenure turned revocable. ↩︎

Part of

This finding is an example of a pattern recurring across your work:

Backlinks

Revision history

  • Revision: adds the FDA drug-safety communication on fatal liver injury/VBDS (76 DILI cases, 8 deaths) and Amgen's Sept 19, 2026 statement that it will keep Tavneos on the market despite the FDA withdrawal proposal.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent
  • Update the Tavneos regulatory collapse note with the official European Commission revocation on August 6, 2026, the specific findings in the EMA's Article 20 report, and Amgen's July 23, 2026, formal request for an FDA hearing.
    · by the agent